Skip to main content

Table 1 Baseline clinicopathologic characteristics of patients with first-line treatment

From: Right- and left-sided colorectal cancers respond differently to cetuximab

Clinicopathologic characteristic

 

Cetuximab group

Chemotherapy alone group

P value d

  

All patients

RSCC

LSCRC

P value

 

All patients

RSCC

LSCRC

P value

 

No. of patients

 

110

33

77

–

 

117

61

56

–

0.001*

Median age at diagnosis

    

0.420

    

0.502

0.613

    ≤65 years

 

90 (81.8)

29 (87.9)

62 (80.5)

  

93 (79.5)

50 (82.0)

43 (76.8)

  

    >65 years

 

20 (18.2)

4 (12.1)

15 (19.5)

  

24 (20.5)

11 (18.0)

13 (23.2)

  

Sex

    

0.274

    

0.085

0.404

    Male

 

75 (68.2)

20 (60.6)

55 (71.4)

  

73 (62.4)

43 (70.5)

30 (53.6)

  

    Female

 

35 (31.8)

13 (39.4)

22 (28.6)

  

44 (37.6)

18 (29.5)

26 (46.4)

  

ECOG performance status

    

0.300

    

0.367

0.113

    0

 

49 (44.5)

11 (33.3)

38 (49.4)

  

49 (41.9)

29 (47.5)

20 (35.7)

  

    1

 

58 (52.7)

21 (63.6)

37 (48.1)

  

57 (48.7)

26 (42.6)

31 (55.4)

  

    ≥2

 

3 (2.7)

1 (3.0)

2 (2.6)

  

11 (9.4)

6 (9.8)

5 (8.9)

  

Pathology

    

0.003*

    

0.116

0.608

    Adenocarcinoma

 

101 (91.8)

26 (78.8)

75 (97.4)

  

110 (94.0)

55 (90.2)

55 (98.2)

  

    Mucinous & signet-ring cell

 

9 (8.2)

7 (21.2)

2 (2.6)

  

7 (6.0)

6 (9.8)

1 (1.8)

  

Metastasis

    

0.674

    

0.015*

0.893

    Single

 

67 (60.9)

19 (57.6)

48 (62.3)

  

70 (59.8)

43 (70.5)

27 (48.2)

  

    Multiple

 

43 (39.1)

14 (42.4)

29 (37.7)

  

47 (40.2)

18 (29.5)

29 (51.8)

  

Metastasis resection

 

29 (26.4)

6 (18.2)

23 (29.9)

0.244

 

28 (23.9)

15 (24.6)

13 (23.2)

1.000

0.760

Total cycles of cetuximaba

 

8 (2–29)

9 (2–29)

8 (2–29)

0.537

 

–

–

–

–

–

Total cycles of chemotherapya

 

13 (2–43)

13 (3–38)

13 (2–43)

0.928

 

13 (2–38)

14 (2–38)

13 (4–38)

0.546

0.344

All three active drugsb

 

73 (66.4)

24 (72.7)

49 (63.6)

0.388

 

89 (76.1)

48 (78.7)

41 (73.2)

0.522

0.109

Backbone chemotherapy

    

0.029*

    

0.041*

0.003*

    Oxaliplatin-based

 

37 (33.6)

6 (18.2)

31 (40.3)

  

63 (53.8)

27 (44.3)

36 (64.3)

  

    Irinotecan-based

 

73 (66.4)

27 (81.8)

46 (59.7)

  

54 (46.2)

34 (55.7)

20 (35.7)

  

Bevacizumab during the disease

 

44 (40.0)

15 (45.5)

29 (37.7)

0.525

 

38 (32.5)

24 (39.3)

14 (25.0)

0.116

0.270

Recurrent diseasec

 

31 (28.2)

6 (18.2)

25 (32.5)

0.230

 

32 (27.4)

18 (29.5)

14 (25.0)

0.679

1.000

  1. aThe values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses. b Patients who received 5-fluorouracil, oxaliplatin, and irinotecan during the course of their disease. c Patients who had metastatic disease after curative-intent primary tumor resection. d Patient characteristics were compared between the cetuximab and chemotherapy groups. ECOG, Eastern Cooperative Oncology Group; RSCC, right-sided colon cancer; LSCRC, left-sided colorectal cancer
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us